share_log

HC Wainwright & Co. Initiates Coverage On Acurx Pharmaceuticals With Buy Rating, Announces Price Target of $14

Benzinga Real-time News ·  Dec 19, 2022 06:11

HC Wainwright & Co. analyst Ed Arce initiates coverage on Acurx Pharmaceuticals (NASDAQ:ACXP) with a Buy rating and announces Price Target of $14.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment